Trial · NCT02064868
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Worsening Heart Failure (WHF) / All Cause of Deaths Through Day 5 | Serelaxin + Standard of Care | 4.95 | Percentage of Participants | ||
| Percentage of Participants With Worsening Heart Failure (WHF) / All Cause of Deaths Through Day 5 | Standard of Care (SOC) | 6.94 | Percentage of Participants | ||
| Percentage of Participants With In-hospital Worsening Heart Failure/All-Cause Death/Readmission for Heart Failure Through Day 14 | Serelaxin + Standard of Care | 8.49 | Percentage of Patients | ||
| Percentage of Participants With In-hospital Worsening Heart Failure/All-Cause Death/Readmission for Heart Failure Through Day 14 | Standard of Care (SOC) | 10.63 | Percentage of Patients | ||
| Percentage of Participants With Persistent Sign or Symptoms of Heart Failure / Non-Improvement at Any Post Baseline Visit Through Day 5 | Serelaxin + Standard of Care | 86 | 95% Confidence Interval 84 to 87 | Percentage of Participants | |
| Percentage of Participants With Persistent Sign or Symptoms of Heart Failure / Non-Improvement at Any Post Baseline Visit Through Day 5 | Standard of Care (SOC) | 91 | 95% Confidence Interval 89 to 93 | Percentage of Participants | |
| Percentage of Participants With Renal Deterioration at Any Post Baseline Visit Through Day 14 | Serelaxin + Standard of Care | 36 | 95% Confidence Interval 34 to 38 | Percentage of Participants | |
| Percentage of Participants With Renal Deterioration at Any Post Baseline Visit Through Day 14 | Standard of Care (SOC) | 44 | 95% Confidence Interval 40 to 47 | Percentage of Participants | |
| Length of Index Hospital Stay | Serelaxin + Standard of Care | 251.28 | Standard Deviation 162.368 | hours | |
| Length of Index Hospital Stay | Standard of Care (SOC) | 243.59 | Standard Deviation 160.270 | hours | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Serelaxin + Standard of Care | Patients with any AE through Day 5 | 58.13 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Standard of Care (SOC) | Patients with any AE through Day 5 | 56.04 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Serelaxin + Standard of Care | Patients with any SAE through Day 14 | 12.38 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Standard of Care (SOC) | Patients with any SAE through Day 14 | 11.97 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Serelaxin + Standard of Care | All cause deaths through Day 5 | 0.58 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Standard of Care (SOC) | All cause deaths through Day 5 | 0.67 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Serelaxin + Standard of Care | All cause deaths through Day 14 | 1.91 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Standard of Care (SOC) | All cause deaths through Day 14 | 2.01 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Serelaxin + Standard of Care | All cause deaths through Day 30 | 3.30 | Percentage of participants | |
| Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients | Standard of Care (SOC) | All cause deaths through Day 30 | 4.25 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02064868/results